Profile data is unavailable for this security.
About the company
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
- Revenue in USD (TTM)3.73m
- Net income in USD-10.31m
- Incorporated2018
- Employees8.00
- LocationMarker Therapeutics Inc2450 HOLCOMBE BLVDSUITE BCM-A, MS: BCM251HOUSTON 77021United StatesUSA
- Phone+1 (713) 400-6400
- Fax+1 (302) 655-5049
- Websitehttps://markertherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unity Biotechnology Inc | 0.00 | -27.86m | 24.43m | 19.00 | -- | 1.24 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Tron Pharmaceuticals Inc | 1.01m | -549.47k | 24.66m | 50.00 | -- | -- | -- | 24.42 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Geovax Labs Inc | 300.68k | -26.92m | 24.74m | 17.00 | -- | -- | -- | 82.28 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -12.20m | 24.76m | 6.00 | -- | -- | -- | -- | -0.6924 | -0.6924 | 0.00 | -0.1201 | 0.00 | -- | -- | 0.00 | -839.15 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | -- | -- | -- | -- | 26.85 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.88m | 25.31m | 16.00 | -- | -- | -- | -- | -0.7299 | -0.7299 | 0.00 | -0.4488 | 0.00 | -- | -- | 0.00 | -350.36 | -- | -5,244.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| Cue Biopharma Inc | 8.30m | -46.96m | 25.49m | 53.00 | -- | 1.18 | -- | 3.07 | -0.9743 | -0.9743 | 0.1718 | 0.4445 | 0.1437 | -- | 5.56 | 156,528.30 | -81.32 | -57.45 | -113.52 | -68.41 | -- | -- | -566.02 | -810.87 | -- | -- | 0.2242 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Nuo Therapeutics Inc | 1.03m | -2.69m | 25.63m | -- | -- | 41.78 | -- | 24.92 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Lipocine Inc | 4.80m | -8.49m | 25.88m | 17.00 | -- | 1.22 | -- | 5.39 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Marker Therapeutics Inc | 3.73m | -10.31m | 26.23m | 8.00 | -- | 2.70 | -- | 7.04 | -1.16 | -1.17 | 0.4196 | 1.09 | 0.2217 | -- | 1.76 | 465,930.00 | -61.30 | -53.74 | -71.74 | -62.25 | -- | -- | -276.53 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -21.07m | 26.46m | 25.00 | -- | 0.6918 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| IGC Pharma Inc | 1.06m | -13.30m | 26.62m | 67.00 | -- | 3.38 | -- | 25.06 | -0.2104 | -0.2104 | 0.0167 | 0.1042 | 0.0809 | 0.2028 | 8.40 | 15,850.75 | -101.29 | -42.46 | -122.91 | -46.07 | 60.36 | 20.95 | -1,252.64 | -730.00 | 1.16 | -- | 0.0173 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Impact Biomedical Inc | 0.00 | -4.25m | 26.79m | 1.00 | -- | 1.15 | -- | -- | -0.3694 | -0.3694 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -9.59 | -- | -15.04 | -- | -- | -- | -- | -- | -- | -5.12 | 0.3377 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -25.90m | 27.07m | 8.00 | -- | 1.38 | -- | -- | -4.97 | -4.97 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -89.41 | -95.57 | -117.09 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Aeon Biopharma Inc | 0.00 | -305.52m | 27.23m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -2.01m | 28.12m | -- | -- | -- | -- | -- | -0.1562 | -0.1562 | 0.00 | -0.2067 | 0.00 | -- | -- | -- | -199.80 | -- | -- | -- | -- | -- | -- | -- | -- | -15.58 | -- | -- | -- | -- | -72.57 | -- | -- | -- |
| ImmuCell Corp | 23.22m | -4.05m | 28.20m | 74.00 | -- | 1.20 | -- | 1.21 | -0.521 | -0.521 | 2.99 | 2.99 | 0.5409 | 2.32 | 13.47 | 293,961.10 | -9.43 | -5.16 | -10.50 | -5.53 | 26.05 | 40.04 | -17.44 | -12.64 | 0.7668 | -7.43 | 0.3243 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Data as of Sep 20 2024. Currency figures normalised to Marker Therapeutics Inc's reporting currency: US Dollar USD
9.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aisling Capital Management LPas of 30 Jun 2024 | 314.29k | 3.52% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 235.81k | 2.64% |
| AR Asset Management, Inc.as of 30 Jun 2024 | 70.70k | 0.79% |
| Wedbush Securities, Inc. (Investment Management)as of 30 Jun 2024 | 69.50k | 0.78% |
| Geode Capital Management LLCas of 30 Jun 2024 | 68.24k | 0.77% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 38.85k | 0.44% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 22.12k | 0.25% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 20.95k | 0.24% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 20.28k | 0.23% |
| Creative Planning LLCas of 30 Jun 2024 | 17.31k | 0.19% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
